文献速递咽喉与嗓音

OMNI嗓音用力量表在内收型痉挛性发声障碍治疗中的验证

Validation of the OMNI vocal effort scale in the treatment of adductor spasmodic dysphonia.
PubMed 文献 · Laryngoscope · 2018-10-12

本研究为前瞻性验证研究,纳入226名参与者(178例接受肉毒素注射的内收型痉挛性发声障碍患者和48名无嗓音障碍对照),评估OMNI嗓音用力量表(OMNI-VES)在嗓音相关感知用力中的有效性。

要点

  • OMNI-VES可用于评估ADSD患者嗓音相关感知用力。
  • ADSD患者OMNI-VES评分显著高于正常对照。
  • 肉毒素注射后1个月OMNI-VES评分显著下降。

核心结论

  • OMNI-VES是评估ADSD患者嗓音相关感知用力的有效工具,可用于评价肉毒素注射治疗的反应。

研究设计与样本

  • 前瞻性验证研究,纳入226名参与者,其中178例接受肉毒素注射的ADSD患者和48名无嗓音障碍对照。

主要发现

  • OMNI-VES与V-RQOL评分呈弱相关(Tau-b = -0.252,P < 0.001),与CAPE-V无显著相关性。
  • ADSD患者OMNI-VES评分显著高于正常对照,分别为5.07 ± 2.18和1.47 ± 2.28(P值 < 0.0001)。
  • 17例患者亚组在注射后1个月OMNI-VES平均评分从6 ± 2.4显著改善至3.4 ± 2.8(P值 = 0.0003)。

关键数值与推荐

  • OMNI-VES与V-RQOL相关性Tau-b = -0.252(P < 0.001)。
  • ADSD组与对照组OMNI-VES评分分别为5.07 ± 2.18和1.47 ± 2.28(P < 0.0001)。
  • 注射后1个月OMNI-VES评分从6 ± 2.4降至3.4 ± 2.8(P = 0.0003)。

临床怎么用

  • 临床可使用OMNI-VES快速评估ADSD患者嗓音相关感知用力。
  • OMNI-VES可作为肉毒素注射治疗反应的结局指标。

局限性

  • OMNI-VES与CAPE-V无显著相关性,与V-RQOL仅弱相关。
  • 仅17例患者进行了注射后1个月的重复评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To establish the validity of the OMNI Vocal Effort Scale (OMNI-VES) for resistance exercise, a single-question pictorial scale, in voice-related perceived exertion. Additionally, the study aimed to assess the role of the OMNI-VES as an outcome measurement in the treatment of adductor spasmodic dysphonia (ADSD). METHODS: A prospective validation study was conducted on 226 participants. The case group was comprised of 178 patients receiving botulinum toxin (BTX) injections for ADSD and 48 controls without a voice disorder. Prior to a planned injection, the participants were asked to complete the OMNI-VES and the Voice-Related Quality-of-Life (V-RQOL) questionnaires, and the clinician completed the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V). A subgroup of 17 patients were administered a repeat assessment 1 month after injection. RESULTS: There was a weak correlation between the OMNI-VES and the V-RQOL score (Tau-b = -0.252, P < 0.001), and no significant correlation with the CAPE-V. Participants with ADSD had significantly higher OMNI-VES scores compared with normal controls, 5.07 ± 2.18 and 1.47 ± 2.28, respectively (P value < 0.0001). The average OMNI-VES score significantly improved 1 month following a BTX injection, from 6 ± 2.4 to 3.4 ± 2.8 (P value = 0.0003). Eighty-eight percent of the patients demonstrated a decrease in the OMNI-VES score following injection, whereas only 47% demonstrated an improvement in the V-RQOL score. CONCLUSION: The OMNI-VES is a validated tool for rating perceived voice-related exertion in people with ADSD and can be used for evaluating response to BTX injection treatment. LEVEL OF EVIDENCE: 2b Laryngoscope, 129:448-453, 2019.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Shoffel-Havakuk H, Marks KL, Morton M, et al. Validation of the OMNI vocal effort scale in the treatment of adductor spasmodic dysphonia. Laryngoscope. 2018. PMID: 30315575. doi:10.1002/lary.27430

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。